SENS

Senseonics Holdings, Inc.

$10.03

2.35%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Source: Yahoo Finance
AI summary

Price & performance

1M+11.7%
3M+33.0%
YTD+70.3%
1Y+58.5%
52-week range—
Beta1.73
Full chart and returns against a benchmark

Q-Score

44/ 100

Quality against peers; 50 is the peer median.

Growth65
Risk45
Performance55
Valuation36
Profitability36
Leverage31
Sentiment41
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$35.3M+56.9%
Net income-$69.1M
Net margin-196.0%+153.8 pts
Historical fundamentals

Red flags in filings

1active red flag
Going-concern doubtMar 2, 2026
Filings, findings and the timeline

Revenue exposure

21%of revenue from outside the US
United States79%
Non Us21%
Largest customer53%
Regions, segments, customers and suppliers

Valuation

SENSIndustryP/E—29.61P/S8.843.49EV/EBITDA—18.38P/B6.833.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 9next report, after the close
EPS estimate$-0.52
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate